Evidence map›Paper›PMID 39166076›Full record

ArticleHeliyon2024

Oligandrin from

Stéphane Zingue, Yannick Stéphane Fotsing Fongang, Eric Roger Ossomba, Vanneck Tatsinda, Kevine Kamga Silihe, William Defo Mbou, Balotin Fogang, René Essomba, Jean Rodolphe Chouna, Dieudonné Njamen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stéphane ZingueDepartment of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaounde, 1, P.O. Box 1364, Yaounde, Cameroon.
Yannick Stéphane Fotsing FongangDepartment of Chemistry, Higher Teachers' Training College, University of Maroua, P.O. Box 55, Maroua, Cameroon.
Eric Roger OssombaDepartment of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaounde, 1, P.O. Box 1364, Yaounde, Cameroon.
Vanneck TatsindaDepartment of Chemistry, Faculty of Science, University of Dschang, P.O. Box 67, Dschang, Cameroon.
Kevine Kamga SiliheDepartment of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaounde, 1, P.O. Box 1364, Yaounde, Cameroon.
William Defo MbouDepartment of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaounde, 1, P.O. Box 1364, Yaounde, Cameroon.
Balotin FogangDepartment of Animal Biology and Physiology, Faculty of Science, University of Yaoundé, 1, P.O. Box 812, Yaoundé, Cameroon.
René EssombaDepartment of Microbiology, Parasitology, Hematology and Infectious Diseases, Faculty of Medicine and Biomedical Sciences, University of Yaounde, 1, P.O. Box 1364, Yaounde, Cameroon.
Jean Rodolphe ChounaDepartment of Animal Biology and Physiology, Faculty of Science, University of Yaoundé, 1, P.O. Box 812, Yaoundé, Cameroon.
Dieudonné NjamenDepartment of Animal Biology and Physiology, Faculty of Science, University of Yaoundé, 1, P.O. Box 812, Yaoundé, Cameroon.
Lawrence AyongMalaria Research Unit, Centre Pasteur, Yaoundé, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Recent developments in cancer research indicate that cancer is a manifestation of immune system dysfunction. Many natural anticancer agents developed recently possess immune-modulatory properties. In our ongoing pursuit of anticancer alternatives, we evaluated the immune-modulatory potential of oligandrin, an ent-pimarane type diterpenoid from Methods: we assessed on Breast cancer patients' peripheral blood mononuclear cells (PBMCs) were isolated to assess the effect of oligandrin (0.5, 1, 10, 100, 200 mg/mL) Results: Oligandrin (1, 10, 100 and 200 μg/mL) significantly increased ( Conclusion: Oligandrin is reported for the first time to protect against breast cancer onset and this effect seems to be at least in part attributable to its immune-boosting capacity.

Indexed as

Breast cancerCroton oligandrusCytokinesImmune systemOligandrinOxidative stress

Identifiers

PMID39166076
PMCPMC11334813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.